IGI Logo

Venus Remedies is currently trading at Rs. 312.20, up by 5.15 points or 1.68% from its previous closing of Rs. 307.05 on the BSE.

The scrip opened at Rs. 303.50 and has touched a high and low of Rs. 320.00 and Rs. 303.50 respectively. So far 1129 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 427.30 on 01-Aug-2024 and a 52 week low of Rs. 272.20 on 28-Jan-2025.

Last one week high and low of the scrip stood at Rs. 340.00 and Rs. 303.50 respectively. The current market cap of the company is Rs. 415.91 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.11% and 57.13% respectively.

Venus Remedies has entered into an exclusive license agreement with lnfex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes the company to spearhead the clinical development, registration, and commercialization of MET-X, an innovative Metallo-Beta-Lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with the company holding exclusive marketing rights within India.

Under the terms of the agreement, the company will commence with a Phase I involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcome, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTls), prevalent in hospital settings.

This strategic move is aligned with the company’s extensive experience in antibiotic R&D and critical care, enhancing its leadership in Indian critical care landscape. The company’s formidable position in meropenem marketing and manufacturing will facilitate the integration of MET-X in existing and prospective antibiotic strategies.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.